|
|
News Breaks | | | | September 17, 2012 | | 08:02 EDT |  | ANTH | Anthera announces advancement of blisibimod in Phase 3 development
Anthera Pharmaceuticals provided an update on regulatory discussions for the global development of blisibimod. End of Phase 2 discussions with the FDA have been completed and will allow for the submission of Phase 3 protocols and the initiation of registration studies. Earlier in 2012, Anthera received a written response from the European Medicines Agency nproviding similar development feedback for the blisibimod program. | |
|
News For ANTH From The Last 14 Days Check below for free stories on ANTH the last two weeks. |
|
|
| May 13, 2013 | | 17:25 EDT |  | ANTH | Anthera Pharmaceuticals reports Q1 EPS (6c), consensus (9c)
 Subscribe for More Information | |
|
|
|
|
|
|
